Key facts
- Notable investors include Thematic Technology Transfer, Netherlands Organisation for Scientific Research (Netherlands).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Holland Hybrid Heart
- ·The full record, as it builds
Funding rounds
No funding rounds for Holland Hybrid Heart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Holland Hybrid Heart
Developer of biocompatible artificial organ technology designed for advanced heart failure treatment. The company integrates soft robotics with in situ tissue engineering to create soft, actuated systems with embedded intelligence, biodegradable scaffolds, and cell-free implants that mimic natural motility and include integration with the human body, enabling the healthcare market to offer a viable alternative to donor heart transplantation.
- Sector
- Healthcare
- HQ
- Enschede, New Zealand
- Website
- hollandhybridheart.nl/
- Ownership
- Privately Held (backing)
Holland Hybrid Heart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Holland Hybrid Heart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Holland Hybrid Heart in its N-PORT filings yet. We sweep new filings monthly.